Literature DB >> 31677214

Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.

Venkatesh K Ariyamuthu1, Burhaneddin Sandikci2, Nashila AbdulRahim1, Christine Hwang3, Malcolm P MacConmara3, Ravi Parasuraman4, Ahsen Atis5, Bekir Tanriover1.   

Abstract

BACKGROUND: Kidneys from deceased donors infected with hepatitis C virus (HCV) are underutilized. Most HCV virus-infected donors are designated as Public Health Service increased donors (PHS-IR). Impact of PHS and HCV designations on discard is not well studied.
METHODS: We queried the UNOS data set for all deceased donor kidneys between January 2015 and December 2018. The final study cohort donors (n = 38 702) were stratified into three groups based on HCV antibody (Ab) and NAT status: (a) Ab-/NAT- (n = 35 861); (b) Ab+/NAT- (n = 973); and (c) Ab±/NAT+ (n = 1868). We analyzed utilization/discard rates of these organs, the impact of PHS-IR and HCV designations on discard using multivariable two-level hierarchical logistic regression models, forecasted number of HCV viremic donors/kidneys by 2023.
RESULTS: During the study period, (a) the number of viremic donor kidneys increased 2 folds; (b) the multilevel mixed-effects logistic regression models showed that, overall, the PHS labeling (OR 1.20, CI 95% CI 1.15-1.29) and HCV designation (OR 2.29; 95% CI 2.15-2.43) were independently associated with increased risk of discard; (c) contrary to the general perception, PHS-IR kidneys across all HCV groups, compared to PHS-IR kidneys were more likely to be discarded; (d) we forecasted that the number of kidneys from HCV viremic donor kidneys might increase from 1376 in 2019 to 2092 in 2023.
CONCLUSION: Hepatitis C virus viremic kidneys might represent 10%-15% of deceased donor organ pool soon with the current rate of the opioid epidemic. PHS labeling effect on discard requires further discussion of the utility of this classification.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  discard; hepatitis C virus; nucleic acid testing; public health service - increased risk; utilization

Mesh:

Year:  2019        PMID: 31677214     DOI: 10.1111/tid.13204

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

1.  Reversal of Donor Hepatitis C Virus-Related Mesangial Proliferative GN in a Kidney Transplant Recipient.

Authors:  Pascale Khairallah; Satoru Kudose; Heather K Morris; Lloyd E Ratner; Sumit Mohan; Jai Radhakrishnan; Jae-Hyung Chang
Journal:  J Am Soc Nephrol       Date:  2020-09-16       Impact factor: 10.121

2.  Liver Outcome in Renal Transplant Recipients Who Acquired Hepatitis C Infection From an Infected Graft: Study Based on Liver Biopsy Findings.

Authors:  Jiten P Kothadia; Anshul Bhalla; Miklos Z Molnar; Rahul Mohan; Vasanthi Balaraman; Manish Talwar; Ryan Helmick; Corey Eymard; Ian Clark; Richa Jain; Thomas W Faust; Jason M Vanatta; James D Eason; Satheesh P Nair
Journal:  Transplant Direct       Date:  2022-05-26

3.  Center-level Utilization of Hepatitis C Virus-positive Donors for Orthotopic Heart Transplantation.

Authors:  Lauren V Huckaby; Laura M Seese; Robert Handzel; Yisi Wang; Gavin Hickey; Arman Kilic
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 4.939

4.  Optimizing Utilization of Kidneys from Hepatitis C-Positive Kidney Donors.

Authors:  Venkatesh K Ariyamuthu; Bekir Tanriover
Journal:  Clin J Am Soc Nephrol       Date:  2021-01-15       Impact factor: 8.237

5.  Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Authors:  Zoe A Stewart; Jeffrey Stern; Nicole M Ali; Harmit S Kalia; Karen Khalil; Srijana Jonchhe; Elaina P Weldon; Rebecca A Dieter; Tyler C Lewis; Nur Funches; Sudara Crosby; Monique Seow; Jonathan C Berger; Nabil N Dagher; Bruce E Gelb; Anthony C Watkins; Nader Moazami; Deane E Smith; Zachary N Kon; Stephanie H Chang; Alex Reyentovich; Luis F Angel; Robert A Montgomery; Bonnie E Lonze
Journal:  Transplant Direct       Date:  2021-09-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.